New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2013
08:46 EDTOWW, DGIT, APP, NQ, YUM, MRK, SINA, XRX, AVNR, LLY, JCPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: NQ Mobile (NQ), up 10%... Sina (SINA), up 6.5%. ALSO HIGHER: Digital Generation (DGIT), up 38% after selling television ad delivery business for $485M, announcing plan to form new company that will hold DG's online business... Avanir Pharmaceuticals (AVNR), up 9% after announcing an agreement to co-promote Merck (MRK) therapies in U.S. long-term care institutions... Eli Lilly (LLY), up 4.3% after lung cancer drug met endpoint in trial... Xerox (XRX), up 3% following upgrade to Buy from Neutral at Citigroup... J.C. Penney (JCP), up 1.4% after Bill Ackman resigns from board. DOWN AFTER EARNINGS: American Apparel (APP), down 4.5%. ALSO LOWER: Yum! Brands (YUM), down 3.2% after announcing July same-store sales in its China division fell 13%, including a 16% drop at KFC stores... Orbitz Worldwide (OWW), down 12% after announcing PAR Capital Management has sold 8.1M of its 24.6M shares of Orbitz Worldwide stock.
News For JCP;XRX;YUM;LLY;SINA;NQ;AVNR;MRK;APP;DGIT;OWW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 29, 2015
08:39 EDTMRKMerck says Phase 3 Emend data shows it provides 'greater protection' from nausea
Merck announced results from a Phase 3 study investigating the safety and efficacy of single-dose Emend for Injection, Merck’s substance P/neurokinin receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting, or CINV, in adult cancer patients receiving moderately emetogenic chemotherapy, or MEC. In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose Emend for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on “Supportive Care in Cancer” in Copenhagen.
05:16 EDTLLYEli Lilly, Immunocore enter clinical trial collaboration
Subscribe for More Information
June 26, 2015
09:15 EDTLLYEli Lilly price target raised to $102 from $97 at Piper Jaffray
Subscribe for More Information
07:50 EDTLLYEli Lilly price target raised to $92 from $77 at Leerink
Subscribe for More Information
07:34 EDTLLYEli Lilly volatility elevated as shares near record high
Subscribe for More Information
05:17 EDTLLYEli Lilly, Adocia report positive Phase 1b topline results for BioChaperone Lisp
Subscribe for More Information
June 25, 2015
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AT&T (T) upgraded to Buy from Neutral at BofA/Merrill... Eli Lilly (LLY) upgraded to Buy, added to US 1 List at BofA/Merrill... Finish Line (FINL) upgraded to Buy from Neutral at B. Riley... Gran Tierra (GTE) upgraded to Buy from Hold at Canaccord... Greenhill & Co. (GHL) upgraded to Buy from Sell at Goldman... Magnum Hunter (MHR) upgraded to Equalweight from Underweight at Capital One... Marathon Oil (MRO) upgraded to Buy from Neutral at UBS... Newpark Resources (NR) upgraded to Strong Buy from Outperform at Raymond James... Office Depot (ODP) upgraded to Outperform from Market Perform at Telsey Advisory... Quanex (NX) upgraded to Outperform from In-Line at Imperial Capital... Vestas Wind (VWDRY) upgraded to Outperform from Neutral at Exane BNP Paribas... Web.com (WWWW) upgraded to Buy from Neutral at B. Riley... NRG Yield upgraded to Outperform from Market Perform at Avondale.
07:39 EDTLLYEli Lilly upgraded to Buy, added to US 1 List at BofA/Merrill
As previously reported, BofA/Merrill upgraded Eli Lilly to Buy from Neutral and added it to the US 1 List. The firm raised estimates and increased its price target to $101 from $74 based on more bullish pipeline expectations. BofA/Merrill highlights eva and sola pipelines, which have high risk/reward opportunities with Phase III data in the next 12-18 months. Firm forecasts peak sales of $1.5B for eva and $2B for sola and said success in either of these programs would result in significant upside to estimates.
06:44 EDTLLYEli Lilly upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
06:07 EDTLLYEli Lilly reports UK court rules in favor of Lilly in Alimta vitamin patent suit
Eli Lilly announced that the Court of Appeal has ruled that the Alimta vitamin regimen patent would be indirectly infringed by a generic competitor that had stated its intent to market certain alternative salt forms of pemetrexed in the United Kingdom prior to the UK patent's expiration in June 2021. Specifically, the Court of Appeal held that commercialization of these alternative salt forms in the products as proposed would constitute indirect infringement by supplying an essential means for putting the patented invention into effect. The decision came in the case of Actavis v. Eli Lilly and Company. The Court of Appeal also held there was no difference between the law in the UK and that in France, Italy and Spain as it relates to indirect infringement, and so reversed the High Court's decision granting declarations of noninfringement over the Alimta vitamin regimen patents in those countries. Actavis may seek permission to appeal the decision to the UK Supreme Court. In addition, Actavis has stated it may ask the High Court to decide whether a different proposed product would infringe the patent. The Court of Appeal has ruled that the High Court will need to decide whether it will hear this new claim. If the High Court decides to hear Actavis' case on the different proposed product, Lilly will defend the case vigorously. In Europe, the compound patents for Alimta remain in force and are expected to provide exclusivity through December 2015. This decision increases the likelihood that the vitamin regimen patents for Alimta will provide exclusivity in the UK, France, Italy and Spain through June 2021.
June 24, 2015
10:26 EDTJCPStocks with call strike movement; TWTR JCP
Twitter (TWTR) December 40 call option implied volatility increased 1% to 44, J.C. Penney (JCP) November 20 call option implied volatility decreased 5% to 42 according to IVolatility.
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
07:03 EDTOWWOrbitz offers complimentary TSA PreCheck for top tier rewards members
Subscribe for More Information
June 23, 2015
07:17 EDTAPPAmerican Apparel unveils Dov Charney’s “sordid” behavior, NY Post reports
American Apparel disclosed “sordid details” of the investigation into founder and former CEO Dov Charney, who recently filed a defamation suit against the company, that resulted in his firing, the New York Post reports, citing a court filing. The filing says that the company found “voluminous evidence” that Charney had “sexual liaisons” with employees and models, exchanged pornographic emails and text messages, and took videos and photographs of these encounters using company property, the report says. Reference Link
June 22, 2015
12:13 EDTSINAMorgan Stanley reports 5.0% passive stake in SINA
Subscribe for More Information
11:31 EDTLLYActinobac Biomed signs licensing agreemnt with Eli Lilly unit Elanco
Subscribe for More Information
09:08 EDTAPPAmerican Apparel sued by former CEO Charney, LA Times reports
Subscribe for More Information
08:39 EDTLLYBernstein pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
07:49 EDTXRXXerox error-rate reduction not reflected in Street estimates, says Susquehanna
Subscribe for More Information
June 21, 2015
13:14 EDTMRKMerck shares could return 25%, Barron's says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use